| Neptune Technologies & Bioressources Inc. reports first quarter results |
| Friday, October 10 2008 | |||
Neptune Technologies & Bioressources Inc. reports first quarter resultsLaval, Québec, CANADA – October 10th, 2008 – Neptune Technologies & Bioressources Inc. (“Neptune”) (NASDAQ.NEPT - TSX.V.NTB) today announced financial results for the fiscal 2009 first quarter ended August 31, 2008. Total revenue for the three-month period ended August 31, 2008 was $2,366,000 compared to $2,085,000 for the first quarter ended August 31, 2007, representing an increase of 13.5%. The Company substantially decreased its net loss by 43% to $599,000, or $0.016 per share, for the three-month period ended August 31, 2008, compared to a net loss of $1,051,000, or $0.029 per share, for the three-month period ended August 31, 2007. Excluding non-monetary items, stock option based compensation and amortization, Neptune would have generated a profit of $344,000 for the three-month period ended August 31, 2008. Neptune continues to generate positive cash flow during the three months ended August 31, 2008 and the Company’s cash, cash equivalents and short-term deposits amounted to $2,151,000 at August 31, 2008. In addition, the Company announced recently that it successfully completed a $2,750,000 debenture financing to be used to support the achievement of several value-creating development and commercialization milestones of Acasti Pharma, its pharmaceutical subsidiary. About Neptune Neptune Technologies and Acasti Pharma Contact:
Neptune Technologies & Bioressources Inc. Acasti Pharma Inc. Toni Rinow, Ph.D., MBA Corporate Development & Investor Relations (450) 687-2262 This e-mail address is being protected from spambots, you need JavaScript enabled to view it
|